It indicated that CNAs of ErbB family predicted overall survival in patients with EGFR-activating mutations but not in wild type EGFR. Findings of this study demonstrated that CNAs of ErbB family provided prognosis prediction in patients with EGFR-activating mutations and provided potential molecular guidance of clinical management of lung adenocarcinoma. The gene discussed is EGFR; the disease is lung adenocarcinoma.